Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Spruce Biosciences, Inc.

< Previous 1 2 Next >
Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Announces $53.6 Million Private Placement Financing
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences to Participate in the SVB Securities Global Biopharma Conference
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences to Participate in November Investor Conferences
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences to Participate in June Investor Conferences
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Announces Acceptance of Abstract for Presentation at ENDO 2022 Annual Conference
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences to Participate in May Investor Conferences
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Appoints Libbie Mansell, Ph.D., M.B.A., R.A.C., as Chief Regulatory and Quality Officer
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Appoints Will Charlton, M.D., M.A.S., as Chief Medical Officer
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Provides Clinical Program Updates and Outlook for 2022
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Appoints Javier Szwarcberg, M.D., MPH as Chief Executive Officer
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences to Participate in the Piper Sandler 33rd Annual Healthcare Conference
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Appoints Mike Grey as Interim CEO
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences to Participate in September Investor Conferences
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences to Host Virtual R&D Day on August 25, 2021
From Spruce Biosciences, Inc.
Via Business Wire
Spruce Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at 23rd European Congress of Endocrinology
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences to Participate in the RBC Capital Markets Global Healthcare Conference
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.